摘要
目的比较前列腺癌(PCa)与前列腺增生(BPH)合并前列腺炎患者金属基质蛋白酶(MMPs)表达。方法选择确诊为PCa患者28例(PCa组)、BPH合并前列腺炎患者30例(BPH组)。采用ELISA法检测血清MMP-2、MMP-9和MMP-14水平,采用放免法检测血清前列腺特异性抗原(PSA)水平,采用免疫组化法对病变组织中MMP-2、MMP-9、MMP-14的阳性表达率进行判定;比较两组患者MMPs及PSA。结果 PCa组患者血清MMP-2、MMP-9、MMP-14和PSA水平均高于BPH组(均P<0.05)。PCa组患者病变组织中MMP-2、MMP-9和MMP-14的阳性表达率为50.0%、53.6%和42.9%,分别高于BPH组的20.0%、10.0%和16.7%(均P<0.05)。结论 PCa与BPH合并前列腺炎患者MMPs表达明显不同,有助于对两者作出鉴别诊断;MMPs家族在PCa中表达的变化可为发病机制的研究提供参考。
Objective To investigate the expression of matrix metalloproteinases(MMPs) in patients with prostate cancer and prostatic hyperplasia combined with prostatitis. Methods Twenty eight patients with prostate cancer(PCa group) and 30 patients with benign prostatic hyperplasia and prostatitis(BPH group) admitted from November 2014 to November 2015 were enrolled in the study. Serum levels of MMP-2, MMP-9, MMP-14 and prostate special antigen(PSA) were measured by enzyme-linked immunosorbent assay(ELISA) and radioimmunoassay, respectively. The expressions of MMP-2, MMP-9 and MMP-14 in tissue samples were detected by immunohistochemistry. Results The serum levels of MMP-2, MMP-9, MMP-14 and PSA in patients with prostate cancer were higher than those in BPH group(P<0.05).The positive rates of MMP-2, MMP-9and MMP-14 in tissue of PCa patients were 50.0%, 53.6% and 42.9%, which were higher than those in BPH group(20.0%,10.0%, 16.7%, respectively)(P<0.05). Conclusion The serum levels and tissue expression of MMP-2, MMP-9 and MMP-14 in prostate cancer are higher than those in patients of benign prostatic hyperplasia patients with prostatitis, indicating that MMPs may be associated with the occurrence and development of prostate cancer.
出处
《浙江医学》
CAS
2017年第9期720-722,共3页
Zhejiang Medical Journal
基金
浙江省医药卫生科技平台项目(2017ZD008)
